drugset / Trial / NCT02467517

Ketamine and Neuropathic Pain

NCT02467517

Phase 2 Unknown 22 enrolled University Hospital, Clermont-Ferrand
RandomizedCrossoverDouble-blindTreatment

Summary

The primary outcome is to compare the analgesic efficacy of intravenous ketamine treatment to that of a placebo in patients with refractory neuropathic pain. The secondary outcomes are: 1. \- To compare the additive analgesic efficacy of prior administration of magnesium sulfate to that of placebo and ketamine only, on the effectiveness of intravenous ketamine treatment, 2. \- To study the evolution time of pain and analgesia after the intravenous administration of ketamine and placebo, 3. \- To study the correlation of the analgesic response to administered products respectively ketamine, ketamine and magnesium sulfate, placebo.

Timeline

Start
2015-11
Primary completion
2018-03
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule Intravenous
Subject Magnesium Sulfate Other / unclassified

Indications